Department of Cardiology, Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
Department of Cardiology, University of Parma, Parma, Italy.
Nat Rev Cardiol. 2024 May;21(5):283-298. doi: 10.1038/s41569-023-00953-4. Epub 2023 Nov 24.
Despite prompt epicardial recanalization in patients presenting with ST-segment elevation myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) is still fairly common and is associated with poor prognosis. Various pharmacological and mechanical strategies to treat CMVO have been proposed, but the positive results reported in preclinical and small proof-of-concept studies have not translated into benefits in large clinical trials conducted in the modern treatment setting of patients with STEMI. Therefore, the optimal management of these patients remains a topic of debate. In this Review, we appraise the pathophysiological mechanisms of CMVO, explore the evidence and provide future perspectives on strategies to be implemented to reduce the incidence of CMVO and improve prognosis in patients with STEMI.
尽管在出现 ST 段抬高型心肌梗死(STEMI)的患者中进行了及时的心脏外膜再通,但冠状动脉微血管阻塞和功能障碍(CMVO)仍然相当常见,并与不良预后相关。已经提出了各种治疗 CMVO 的药理学和机械策略,但在现代 STEMI 患者治疗环境中进行的大型临床试验中,并未观察到临床前和小型概念验证研究中报告的阳性结果转化为获益。因此,这些患者的最佳管理仍然是一个有争议的话题。在这篇综述中,我们评估了 CMVO 的病理生理机制,探讨了相关证据,并就减少 STEMI 患者 CMVO 发生率和改善预后的策略提供了未来的观点。